Jean-Claude Thiranos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jean-Claude Thiranos has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alain Wynckel
Néphrologie, CHU, Reims, France
1 shared publication - Brigitte Tardy-Poncet
CHU and Université Jean Monnet, Saint-Etienne, Saint Etienne, France
1 shared publication - Christine Biron-Andreani
Haemophilia Treatment Centre, University Hospital of Montpellier, Montpellier, France
1 shared publication - Emmanuel De Maistre
Haemostasis Unit University Hospital of Dijon Dijon France
1 shared publication - Jerome Morel
Laboratoire Interuniversitaire de Biologie de la Motricité Université Jean Monnet Saint Etienne, Lyon 1, Université Savoie Mont‐Blanc Saint Etienne France
1 shared publication - Judith Villacorta-Torres
Intensive Care Unit, University Hospital of Marseille, Marseille, France.
1 shared publication
Latest Publications
- Open Access
- 1 December 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 396
Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial
Introduction: The aim of this study was to collect data in France in patients with heparin-induced thrombocytopenia who required parenteral anticoagulation and for whom other non-heparin anticoagulant therapies were contraindicated including patients with renal failure, cross-reactivity to danaparoid or at high hemorrhagic risk.Methods: A total of 20 patients, of mean age 72 ± 10 years, were enrolled in this open-label, multicenter clinical study. Exploratory statistical data analysis was performed with descriptive interpretation of intra-individual comparisons using simple univariate statistics.Results: The diagnosis of HIT was confirmed in 16 subjects by an independent scientific committee. Fourteen patients (70 %) were in an intensive care unit during the course of the study. Patients were treated with argatroban for a mean duration of 8.5 ± 6.1 days. The mean starting dose of argatroban was 0.77 ± 0.45 μg/kg/min. Platelet recovery was rapid.aPTT and anti-IIa activity assays were used to monitor the dose of argatroban. The mean baseline aPTT value was 45.0 ± 9.8 sec and increased to 78.2 ± 35.8 sec two hours after initiating argatroban. At this time mean argatroban concentration was 0.34 ± 0.16 and 0.61 ± 0.28 μg/ml using ECT and TT measurements, respectively. New and/or extended thromboses were reported in 25 % of patients and major bleedings were documented in 15 %. Six patients died due to their underlying medical condition.Conclusion: Considering its hepatic elimination and its short half-life, argatroban can be considered as a safe therapeutic option in HIT patients at high hemorrhagic risk and with renal failure, particularly in an ICU setting.
- 1 December 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 396
Open AccessArgatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial
Introduction: The aim of this study was to collect data in France in patients with heparin-induced thrombocytopenia who required parenteral anticoagulation and for whom other non-heparin anticoagulant therapies were contraindicated including patients with renal failure, cross-reactivity to danaparoid or at high hemorrhagic risk.Methods: A total of 20 patients, of mean age 72 ± 10 years, were enrolled in this open-label, multicenter clinical study. Exploratory statistical data analysis was performed with descriptive interpretation of intra-individual comparisons using simple univariate statistics.Results: The diagnosis of HIT was confirmed in 16 subjects by an independent scientific committee. Fourteen patients (70 %) were in an intensive care unit during the course of the study. Patients were treated with argatroban for a mean duration of 8.5 ± 6.1 days. The mean starting dose of argatroban was 0.77 ± 0.45 μg/kg/min. Platelet recovery was rapid.aPTT and anti-IIa activity assays were used to monitor the dose of argatroban. The mean baseline aPTT value was 45.0 ± 9.8 sec and increased to 78.2 ± 35.8 sec two hours after initiating argatroban. At this time mean argatroban concentration was 0.34 ± 0.16 and 0.61 ± 0.28 μg/ml using ECT and TT measurements, respectively. New and/or extended thromboses were reported in 25 % of patients and major bleedings were documented in 15 %. Six patients died due to their underlying medical condition.Conclusion: Considering its hepatic elimination and its short half-life, argatroban can be considered as a safe therapeutic option in HIT patients at high hemorrhagic risk and with renal failure, particularly in an ICU setting.